First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study
Background In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India). Materials and methods A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to Novembe...
Gespeichert in:
Veröffentlicht in: | Herz 2022-10, Vol.47 (5), p.449-455 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 455 |
---|---|
container_issue | 5 |
container_start_page | 449 |
container_title | Herz |
container_volume | 47 |
creator | Akyüz, Ali Rıza Konuş, Ali Hakan Çırakoğlu, Ömer Faruk Şahin, Sinan Kul, Selim Korkmaz, Levent |
description | Background
In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India).
Materials and methods
A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study.
Results
The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days.
Conclusion
Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves. |
doi_str_mv | 10.1007/s00059-021-05069-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8512594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2719589033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-5ecef8de0abe1b906ff2615a4973907008678776eda2b05f072bb4a43fbeed653</originalsourceid><addsrcrecordid>eNp9kU1uFDEUhC0EIpPABVi1xIZNh-f_NgskFBFACmIDa8vd_XrGUY892O4JcxvOwsnwMBEIFqy8qK9K9VyEPKNwSQH0ywwA0rTAaAsSlGnFA7KiispWKcMekhVwAa0xXJ-R85xvAag0DB6TMy6U4FrIFVlf-5RLg992mDyGAXNz58umcT--B7xrejfPMYa26i6Mrp-x-XjYu7kpyYU8uLLBgqlxMRU_NFXY46ujd5dw9lsfXDo0uSzj4Ql5NLk549P794J8uX77-ep9e_Pp3YerNzftICQtrcQBp25EcD3S3oCaJlYPcsJobkADdEp3WiscHetBTqBZ3wsn-NQjjkryC_L6lLtb-i2OA4badLa75Le1i43O27-V4Dd2Hfe2k5RJI2rAi_uAFL8umIvd-jzgPLuAccmWyY52TNWPr-jzf9DbuKRQz7NMUyM7A5xXip2oIcWcE06_y1Cwxx3taUdbd7S_drTHFvxkyhUOa0x_ov_j-gmiFaMD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2719589033</pqid></control><display><type>article</type><title>First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study</title><source>Springer Nature</source><creator>Akyüz, Ali Rıza ; Konuş, Ali Hakan ; Çırakoğlu, Ömer Faruk ; Şahin, Sinan ; Kul, Selim ; Korkmaz, Levent</creator><creatorcontrib>Akyüz, Ali Rıza ; Konuş, Ali Hakan ; Çırakoğlu, Ömer Faruk ; Şahin, Sinan ; Kul, Selim ; Korkmaz, Levent</creatorcontrib><description>Background
In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India).
Materials and methods
A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study.
Results
The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days.
Conclusion
Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves.</description><identifier>ISSN: 0340-9937</identifier><identifier>EISSN: 1615-6692</identifier><identifier>DOI: 10.1007/s00059-021-05069-4</identifier><identifier>PMID: 34643745</identifier><language>eng</language><publisher>Heidelberg: Springer Medizin</publisher><subject>Aorta ; Aortic valve ; Arteries ; Balloon treatment ; Cardiology ; Complications ; Fatalities ; Heart ; Heart valves ; Hypertension ; Internal Medicine ; Medicine ; Medicine & Public Health ; Original ; Original Articles ; Pacemakers ; Patients ; Population studies ; Prostheses ; Sheaths ; Thorax ; Venous access</subject><ispartof>Herz, 2022-10, Vol.47 (5), p.449-455</ispartof><rights>Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021</rights><rights>Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-5ecef8de0abe1b906ff2615a4973907008678776eda2b05f072bb4a43fbeed653</citedby><cites>FETCH-LOGICAL-c451t-5ecef8de0abe1b906ff2615a4973907008678776eda2b05f072bb4a43fbeed653</cites><orcidid>0000-0003-3327-7850</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00059-021-05069-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00059-021-05069-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Akyüz, Ali Rıza</creatorcontrib><creatorcontrib>Konuş, Ali Hakan</creatorcontrib><creatorcontrib>Çırakoğlu, Ömer Faruk</creatorcontrib><creatorcontrib>Şahin, Sinan</creatorcontrib><creatorcontrib>Kul, Selim</creatorcontrib><creatorcontrib>Korkmaz, Levent</creatorcontrib><title>First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study</title><title>Herz</title><addtitle>Herz</addtitle><description>Background
In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India).
Materials and methods
A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study.
Results
The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days.
Conclusion
Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves.</description><subject>Aorta</subject><subject>Aortic valve</subject><subject>Arteries</subject><subject>Balloon treatment</subject><subject>Cardiology</subject><subject>Complications</subject><subject>Fatalities</subject><subject>Heart</subject><subject>Heart valves</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original</subject><subject>Original Articles</subject><subject>Pacemakers</subject><subject>Patients</subject><subject>Population studies</subject><subject>Prostheses</subject><subject>Sheaths</subject><subject>Thorax</subject><subject>Venous access</subject><issn>0340-9937</issn><issn>1615-6692</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1uFDEUhC0EIpPABVi1xIZNh-f_NgskFBFACmIDa8vd_XrGUY892O4JcxvOwsnwMBEIFqy8qK9K9VyEPKNwSQH0ywwA0rTAaAsSlGnFA7KiispWKcMekhVwAa0xXJ-R85xvAag0DB6TMy6U4FrIFVlf-5RLg992mDyGAXNz58umcT--B7xrejfPMYa26i6Mrp-x-XjYu7kpyYU8uLLBgqlxMRU_NFXY46ujd5dw9lsfXDo0uSzj4Ql5NLk549P794J8uX77-ep9e_Pp3YerNzftICQtrcQBp25EcD3S3oCaJlYPcsJobkADdEp3WiscHetBTqBZ3wsn-NQjjkryC_L6lLtb-i2OA4badLa75Le1i43O27-V4Dd2Hfe2k5RJI2rAi_uAFL8umIvd-jzgPLuAccmWyY52TNWPr-jzf9DbuKRQz7NMUyM7A5xXip2oIcWcE06_y1Cwxx3taUdbd7S_drTHFvxkyhUOa0x_ov_j-gmiFaMD</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Akyüz, Ali Rıza</creator><creator>Konuş, Ali Hakan</creator><creator>Çırakoğlu, Ömer Faruk</creator><creator>Şahin, Sinan</creator><creator>Kul, Selim</creator><creator>Korkmaz, Levent</creator><general>Springer Medizin</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3327-7850</orcidid></search><sort><creationdate>20221001</creationdate><title>First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study</title><author>Akyüz, Ali Rıza ; Konuş, Ali Hakan ; Çırakoğlu, Ömer Faruk ; Şahin, Sinan ; Kul, Selim ; Korkmaz, Levent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-5ecef8de0abe1b906ff2615a4973907008678776eda2b05f072bb4a43fbeed653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aorta</topic><topic>Aortic valve</topic><topic>Arteries</topic><topic>Balloon treatment</topic><topic>Cardiology</topic><topic>Complications</topic><topic>Fatalities</topic><topic>Heart</topic><topic>Heart valves</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original</topic><topic>Original Articles</topic><topic>Pacemakers</topic><topic>Patients</topic><topic>Population studies</topic><topic>Prostheses</topic><topic>Sheaths</topic><topic>Thorax</topic><topic>Venous access</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akyüz, Ali Rıza</creatorcontrib><creatorcontrib>Konuş, Ali Hakan</creatorcontrib><creatorcontrib>Çırakoğlu, Ömer Faruk</creatorcontrib><creatorcontrib>Şahin, Sinan</creatorcontrib><creatorcontrib>Kul, Selim</creatorcontrib><creatorcontrib>Korkmaz, Levent</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Herz</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akyüz, Ali Rıza</au><au>Konuş, Ali Hakan</au><au>Çırakoğlu, Ömer Faruk</au><au>Şahin, Sinan</au><au>Kul, Selim</au><au>Korkmaz, Levent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study</atitle><jtitle>Herz</jtitle><stitle>Herz</stitle><date>2022-10-01</date><risdate>2022</risdate><volume>47</volume><issue>5</issue><spage>449</spage><epage>455</epage><pages>449-455</pages><issn>0340-9937</issn><eissn>1615-6692</eissn><abstract>Background
In the present article, we present our first experiences with a new type of balloon-expandable Myval valve (Meril Life Sciences, Gujarat, India).
Materials and methods
A total of 25 consecutive patients who underwent transcatheter aortic valve implantation (TAVI) from June 2020 to November 2020 were included in the study.
Results
The mean age of the study population was 83 (75–87) years; 17 (68%) were female, and 20 (80%) had hypertension. The Society of Thoracic Surgeons (STS) score of the group was 5.4% ± 3.5%. TAVI was performed via the transfemoral route on all patients. In 19 (76%) cases, we started the procedure without predilation. In two (10.5%) cases performed without predilation, the prosthesis did not pass the native valve. We had to implant the valve from the descending aorta in one (4%) patient. We used Prostar XL (Abbott Vascular, Santa Clara, CA, USA) for six (24%) patients and ProGlide (Abbott Vascular) for 19 (76%) patients for vascular closure. Two (8%) in-hospital deaths occurred in our study but there were no deaths in the 30-day and 90-day follow-up. Vascular complications were observed in one (4%) patient. None of the patients in our study had severe paravalvular leak (PVL), while two (8%) patients had moderate PVL. A permanent pacemaker (PPM) was required in two (8%) patients for the indication of complete atrioventricular block. The mean hospital stay for the whole group was 4 (3–7) days.
Conclusion
Based on our experiences, the new balloon-expandable valve Myval is easy to use, efficient, and has only a few negligible drawbacks such as the need for predilation of the sheath. While shaft flexibility may have advantages in some situations including in very tortuous arteries, it may cause some difficulties in alignment of the valves.</abstract><cop>Heidelberg</cop><pub>Springer Medizin</pub><pmid>34643745</pmid><doi>10.1007/s00059-021-05069-4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-3327-7850</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-9937 |
ispartof | Herz, 2022-10, Vol.47 (5), p.449-455 |
issn | 0340-9937 1615-6692 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8512594 |
source | Springer Nature |
subjects | Aorta Aortic valve Arteries Balloon treatment Cardiology Complications Fatalities Heart Heart valves Hypertension Internal Medicine Medicine Medicine & Public Health Original Original Articles Pacemakers Patients Population studies Prostheses Sheaths Thorax Venous access |
title | First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A12%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20experiences%20with%20a%C2%A0new%20balloon-expandable%20Myval%20transcatheter%20aortic%20valve:%20a%C2%A0preliminary%20study&rft.jtitle=Herz&rft.au=Aky%C3%BCz,%20Ali%20R%C4%B1za&rft.date=2022-10-01&rft.volume=47&rft.issue=5&rft.spage=449&rft.epage=455&rft.pages=449-455&rft.issn=0340-9937&rft.eissn=1615-6692&rft_id=info:doi/10.1007/s00059-021-05069-4&rft_dat=%3Cproquest_pubme%3E2719589033%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2719589033&rft_id=info:pmid/34643745&rfr_iscdi=true |